The project developed by Istanbul Technical University (ITU) Faculty of Science and Letters Department of Molecular Biology and Genetics faculty member Prof. Dr. Gizem Dinler Doğanay was deemed worthy of support within the scope of “2023-C3-CANCER” project call opened by Health Institutes of Türkiye (TUSEB).

Prof. Dr. Dinler Doğanay’s project supported by TUSEB involves research and experiments focused on a newly discovered drug molecule that allows primary or combinatorial treatment of C-Raf-dependent cancers, especially non-targetable RAS mutant types.